The team used SPRINTER to analyse nearly 15,000 cancer cells from a patient with non-small cell lung cancer, the most common type of ... also known as circulating tumour DNA (ctDNA). This presents an ...

This is among the first times a ctDNA assay has been used in a clinical trial of early-stage lung cancer patients to identify those most likely to benefit from further treatment. As such ...

The first computer algorithm capable of identifying which tumor cells are driving aggressive cancer growth has been developed by Cancer Research UK-funded scientists from UCL and The Francis Crick ...

GRAIL (GRAL) announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer, or NSCLC, ctDNA Assay in the global TROPION-Lung12 Phase 3 ...

By inferring proliferation rates from single-cell genomics, SPRINTER enhances understanding of tumor evolution and identifies ...

Oleg Gligich, MD, assistant professor at the Columbia University Division of Hematology/Oncology at Mount Sinai Medical Center, discusses utilizing circulating tumor DNA (ctDNA) to assess patients ...

Financially, Immunocore has a strong cash position and stable revenue growth, but concerns remain about the pipeline's ...

A phlebotomist visits the patient’s home to collect the blood drawn in two tubes: one for detecting circulating tumor DNA (ctDNA ... cancer analysis for all solid tumors, including breast, lung ...